BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/28/2014 3:52:00 PM | Browse: 1065 | Download: 1014
Publication Name World Journal of Gastroenterology
Manuscript ID 5253
Country China
Received
2013-08-26 09:43
Peer-Review Started
2013-08-26 21:14
To Make the First Decision
2013-10-14 21:24
Return for Revision
2013-10-19 17:20
Revised
2013-11-13 17:25
Second Decision
2014-01-02 11:01
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-01-02 12:10
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2014-03-09 08:55
Typeset the Manuscript
2014-04-19 17:00
Publish the Manuscript Online
2014-05-07 10:10
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Cell Biology
Manuscript Type Autobiography
Article Title Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells
Manuscript Source Invited Manuscript
All Author List Hang Yuan, Ai-Jun Li, Sen-Lin Ma, Long-Jiu Cui, Bin Wu, Lei Yin and Meng-Chao Wu
Funding Agency and Grant Number
Funding Agency Grant Number
Eastern Hepatobiliary Surgery Hospital of the Second Military Medical University
Corresponding Author Ai-Jun Li, MD, Department of the 2nd Special Treatment, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, No. 225, Changhai Road, Shanghai 200438, China. ajli62@gmail.com
Key Words Hepatocellular carcinoma; Histone deacetylase inhibitors; Autophagy; Sorafenib; Chemoresistance
Core Tip In this study, we investigated the antiproliferative effect of sorafenib in combination with the histone deacetylase inhibitor vorinostatin in human hepatoma cell lines (Hep3B, HepG2, and PLC/PRF/5). We also examined whether the combination therapy was enhanced by the inhibition of autophagy. Our results showed that the combination of vorinostat with sorafenib synergistically reduced cell proliferation in hepatocellular carcinoma cells by inducing apoptosis and cell cycle arrest. Synergistic changes in cell cycle and cell survival regulators were also observed.
Publish Date 2014-05-07 10:10
Citation Yuan H, Li AJ, Ma SL, Cui LJ, Wu B, Yin L, Wu MC. Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells. World J Gastroenterol 2014; 20(17): 4953-4962
URL http://www.wjgnet.com/1007-9327/full/v20/i17/4953.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i17.4953
Full Article (PDF) WJG-20-4953.pdf
Full Article (Word) WJG-20-4953.doc
Manuscript File 5253-Review.doc
Answering Reviewers 5253-Answering reviewers.pdf
Copyright License Agreement 5253-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 5253-Language certificate.pdf
Peer-review Report 5253-Peer review(s).pdf
Scientific Editor Work List 5253-Scientific editor work list.doc